Adaptive Biotechnologies (ADPT) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

ADPT Adaptive Biotechnologies

Watchlist

6.300
+0.140+2.27%

Close Dec 13 16:00 ET

6.300
0.0000.00%

Post 18:42 ET

929.75MMarket Cap-4.70P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Top 3 Health Care Stocks That May Collapse This Quarter
BenzingaDec 11 06:55 ET
Even After Rising 6.5% This Past Week, Adaptive Biotechnologies (NASDAQ:ADPT) Shareholders Are Still Down 77% Over the Past Five Years
Simply Wall StDec 11 06:19 ET
Adaptive Biotechnologies Management to Meet With BTIG
TipRanksDec 4 12:50 ET
CAR T-cell Therapy Strategic Business Research Report 2024-2030: Allogeneic `Off-the-Shelf` CAR T-Cell Therapies Generate New Opportunities in Manufacturing - ResearchAndMarkets.com
BusinesswireDec 4 08:47 ET
Express News | Adaptive Biotechnologies Announces Over 65 Abstracts Featuring Clonoseq® Mrd Testing Across a Range of Blood Cancers to Be Presented at the 66TH Ash Annual Meeting
ReutersDec 3 07:30 ET
Adaptive Biotechnologies Announces Over 65 Abstracts Featuring ClonoSEQ MRD Testing Across a Range of Blood Cancers to Be Presented at the 66th ASH Annual Meeting
GlobeNewswireDec 3 07:30 ET

Comments

This_Guy

Dec 8 17:28

$Nektar Therapeutics (NKTR.US)$
Nektar Therapeutics Announces NKTR-255 Following CD19-directed CAR-T Therapy Enhanced Complete Response Rates in Patients with Relapsed or Refractory Large B-cell Lymphoma at the 66th Annual ASH Meeting
Positive
73% complete response rate at 6 months vs 50% for placebo
5.8-fold improvement in CD8+ CAR-T cell kinetics compared to placebo
Two patients converted from partial to complete response with NKTR-255
Results exceeded historical benchmark data of 41-44% comple...

This_Guy

Dec 8 17:27

$Adaptive Biotechnologies (ADPT.US)$
Adaptive Biotechnologies Announces New Data at the 66th ASH Annual Meeting Highlighting Advances in MRD Testing with clonoSEQ® and Its Impact on Blood Cancer Treatment Decisions
Positive
Phase 3 trial data shows clonoSEQ can help avoid unnecessary transplantation procedures in MCL patients
FELIX study demonstrated 84% treatment response rate with MRD <10⁻⁶
Evidence supports clonoSEQ's effectiveness in early detection of disease progression
Data validates test'...

Jaguar8

Dec 8 16:19

NEWS SATURDAY 12/7

$Adaptive Biotechnologies (ADPT.US)$
Adaptive Biotechnologies Announces New Data at the 66th ASH Annual Meeting Highlighting Advances in MRD Testing with clonoSEQ® and Its Impact on Blood Cancer Treatment Decisions
Adaptive Biotechnologies (ADPT) presented new data at the 66th ASH Annual Meeting showcasing the effectiveness of their clonoSEQ® test in measuring residual disease (MRD) for blood cancer treatment. Key findings from multiple studies demonstrate that achieving MRD lev...

Jaguar8

Aug 29 07:03

NEWS

$Adaptive Biotechnologies (ADPT.US)$
Adaptive Announces IVDR Certification for clonoSEQ® in European Union
Adaptive Biotechnologies (Nasdaq: ADPT) has announced that its clonoSEQ® test has received In Vitro Diagnostic Regulation (IVDR) 2017/746 Class C certification in the European Union. This makes clonoSEQ the first IVDR-certified test for detecting minimal residual disease (MRD) in patients with lymphoid malignancies. The certification allows for broad use in assessing MRD status and chang...

TechWhiz

Jun 28 18:55

Good volume move up. Small caps like adaptive biotechnologies are moving after Nvidia and other big techs took a break.
Should see higher prices from here.

Heat List

Overall

No Data